Synta Pharmaceuticals Corp. announced two publications with results demonstrating the activity of ganetespib in preclinical models and in a clinical treatment setting of triple-negative breast cancer .
http://www.businesswire.com/portal/site/topix/index.jsp?ndmViewId=news_view&newsId=20131121006554&newsLang=en&ndmConfigId=1000639&vnsId=41
http://www.businesswire.com/portal/site/topix/index.jsp?ndmViewId=news_view&newsId=20131121006554&newsLang=en&ndmConfigId=1000639&vnsId=41
No comments:
Post a Comment